I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
Early objective response to avelumab treatment is associate..:
D'Angelo, Sandra P
;
Hunger, Matthias
;
Brohl, Andrew S
...
info:eu-repo/semantics/altIdentifier/pmid/30721341. , 2019
Link:
http://hdl.handle.net/11562/1064845
RT Journal T1
Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma
UL https://suche.suub.uni-bremen.de/peid=base-ftunivveronairis:oai:iris.univr.it:11562_1064845&Exemplar=1&LAN=DE A1 D'Angelo, Sandra P A1 Hunger, Matthias A1 Brohl, Andrew S A1 Nghiem, Paul A1 Bhatia, Shailender A1 Hamid, Omid A1 Mehnert, Janice M A1 Terheyden, Patrick A1 Shih, Kent C A1 Brownell, Isaac A1 Lebbé, Céleste A1 Lewis, Karl D A1 Linette, Gerald P A1 Milella, Michele A1 Schlichting, Michael A1 Hennessy, Meliessa H A1 Bharmal, Murtuza YR 2019 K1 Merkel cell carcinoma K1 Objective response K1 Overall survival K1 PD-L1 K1 Adult K1 Aged K1 80 and over K1 Antibodies K1 Monoclonal K1 Humanized K1 Antineoplastic Agents K1 Immunological K1 B7-H1 Antigen K1 Biomarkers K1 Tumor K1 Carcinoma K1 Merkel Cell K1 Cell Line K1 Cell Survival K1 Female K1 Humans K1 Male K1 Middle Aged K1 Molecular Targeted Therapy K1 Proportional Hazards Models K1 Treatment Outcome K1 Avelumab K1 Endpoint validation JF info:eu-repo/semantics/altIdentifier/pmid/30721341 LK http://hdl.handle.net/11562/1064845 DO http://hdl.handle.net/11562/1064845 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)